ARTICLE | Deals
Lundbeck bolts on Longboard, gains anticonvulsive in $2.6B deal
Danish pharma eyeing growth beyond loss of exclusivity for Rexulti, aiming for broad label in rare epilepsies
October 14, 2024 7:35 PM UTC
Lundbeck’s first major acquisition under new CEO Charl Van Zyl will bring in a late-stage anticonvulsive program that could deliver billion-dollar sales as the company faces a key patent expiration late this decade.
The $2.6 billion takeout of Longboard Pharmaceuticals Inc. (NASDAQ:LBPH) will end that biotech’s four-year run as a standalone neuroscience company, following its spinout from Arena Pharmaceuticals Inc. in 2020...